Skip to content

HIV's impact on TB control: is it time to re-think TB control strategies?

High incidence of IRIS amongst HIV-positive TB patients starting HAART in India

Risk factors for immune reaction to HAART in TB patients studied by French

Rates of TB treatment interruption unaffected by HIV infection or HAART

TB treatment: four month continuation phase better than six months

HAART reduces risk of death or new AIDS in HIV patients with TB

Rifampicin and pyrazinamide treatment for latent TB in HIV patients does not carry high risk of liver injury, but editorial still urges caution

Efavirenz can be used at normal dose with rifampicin, Thais report

Draft guidelines for the treatment of tuberculosis and HIV published by BHIVA